Lynk Pharmaceuticals
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | JAK1Small molecule | Atopic DermatitisRheumatoid Arthritis | |
| Phase 2 | Pan-JAKSmall molecule | Atopic Dermatitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
Est. primary completion 2026-11 · NCT07237568 · CT.gov ↗
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
4 November 2026Filing acceptedZemprocitinibChina accepts the zemprocitinib application in rheumatoid arthritis
CN, NMPA · Lynk Pharmaceuticals · Source ↗
10 April 2026Filing acceptedzemprocitinib (LNK01001)Zemprocitinib NDA accepted by China's NMPA (CDE)
CN, NMPA · Lynk Pharmaceuticals · Source ↗
12 January 2026Topline resultLNK01001 (zemprocitinib)COURAGE-RA (NCT06276998) Phase 3 met its primary endpoint
China · Simcere Pharmaceutical Group · Source ↗
Financial reports
No financial reports recorded.